• Po-Jen Hsiao, Jenq-Shyong Chan, Kun-Lin Wu, Wen-Fang Chiang, Jing-Shu Huang, Chia-Chao Wu, Pauling Chu, and Jin-Shuen Chen.
• Department of Medicine, Division of Nephrology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Republic of China; Department of Internal Medicine, Division of Nephrology, Taoyuan Armed Forces General Hospital, Taiwan, Republic of China.
• J Res Med Sci. 2016 Jan 1; 21: 99.

BackgroundIt is intriguing and imperative that the comparison of the iron preparations in hemodialysis (HD) patients. This study aimed to observe the short-term efficacy of parenteral iron sucrose and ferric chloride in HD patients.Materials And MethodsThis was a consecutive 10-week single-blind study in Taiwan. An intravenous iron supplement of 100 mg/week was administered as an infusion in 100 ml of normal saline, until a total dose of 1000 mg was achieved. The primary outcome was evaluated by the changes in serum hematocrit (Hct) levels. The changes in serum Hct and iron indices were evaluated every 2 weeks for 10 weeks. The results were collected from 21 April to 4 July 2013.ResultsA total of 56 HD patients completed the study. Subjects were randomized into an iron sucrose group (26 patients) and a ferric chloride group (30 patients). Between the two treatment groups, there were no statistically significant differences in the change in serum Hct, ferritin, iron, or total iron binding capacity (P > 0.05). In the iron sucrose group, the increase in Hct levels was statistically significant at weeks 4, 8, and 10. In the ferric chloride group, the increase in Hct levels was statistically significant at week 8. No obvious major side effects were observed in both groups.ConclusionIn the study subjects, parenteral iron sucrose was as effective and safe as ferric chloride for treating anemia in HD patients.

4 keywords...

hide…